Association of CYP2C19*17/*17 Genotype With the Risk of Voriconazole- Associated Squamous Cell Carcinoma

被引：12
|
作者：
Williams, Kiyanna [1 ]
Arron, Sarah T. [2 ]
机构：
[1] Univ Calif San Francisco, Sch Med, San Francisco, CA USA
[2] Univ Calif San Francisco, Dept Dermatol, 1701 Divisadero St,3rd Floor, San Francisco, CA 94115 USA
来源：
JAMA DERMATOLOGY | 2016年 / 152卷 / 06期
关键词：
TRANSPLANT RECIPIENTS; ANTIFUNGAL AGENT; CYP2C19;
D O I：
10.1001/jamadermatol.2016.0351
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：719 / 720
页数：2
相关论文
共 50 条
  • [21] A case report of voriconazole therapeutic drug monitoring in a heterozygous ultrarapid CYP2C19*1/*17 patient
    Quaranta, S.
    Scodavolpe, S.
    Corda, E. D'incan
    Saut, N.
    Berger, P.
    Morange, P. E.
    Lacarelle, B.
    Solas, C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 : 68 - 69
  • [22] Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections
    Hamadeh, Issam S.
    Klinker, Kenneth P.
    Borgert, Samuel J.
    Richards, Ashley I.
    Li, Wenhui
    Mangal, Naveen
    Hiemenz, John W.
    Schmidt, Stephan
    Langaee, Taimour Y.
    Peloquin, Charles A.
    Johnson, Julie A.
    Cavallari, Larisa H.
    PHARMACOGENETICS AND GENOMICS, 2017, 27 (05): : 190 - 196
  • [23] Impact of CYP2C19 genotype on voriconazole exposure and effect of voriconazole on the activity of CYP3A in patients with haematological malignancies
    Huang, Fengru
    Zhou, Chen
    Zhang, Xiao-Yan
    Shen, Miss Ye
    Zhang, Hongwen
    Wang, Yongqing
    Sun, Luning
    XENOBIOTICA, 2021, 51 (10) : 1199 - 1206
  • [24] Inhibitory effect of oral contraceptives on CYP2C19 activity is not significant in carriers of the CYP2C19*17 allele
    Pedersen, Rasmus S.
    Noehr-Jensen, Lene
    Brosen, Kim
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2013, 40 (10): : 683 - 688
  • [25] CYP2C19*17 GAIN OF FUNCTION MUTATION IS ASSOCIATED WITH PEPTIC ULCER DISEASE
    Musumba, C. O.
    Eker, D. V.
    Jorgensen, A.
    Pritchard, D. M.
    Pirmohamed, M.
    GUT, 2012, 61 : A363 - A363
  • [26] CYP17 and CYP2C19 gene polymorphisms in patients with endometriosis
    Bozdag, Gurkan
    Alp, Alpaslan
    Saribas, Zeynep
    Tuncer, Selcuk
    Aksu, Tarik
    Gurgan, Timur
    REPRODUCTIVE BIOMEDICINE ONLINE, 2010, 20 (02) : 286 - 290
  • [27] The measurement of voriconazole-N-oxide in serum can it allow rapid detection of patients with ultrarapid CYP2C19*17/*17 metabolism?
    Bennis, Y.
    Bodeau, S.
    Bouquie, R.
    Deslandes, G.
    Verstuyft, C.
    Gruson, B.
    Lemaire-Hurtel, A. S.
    Chouaki, T.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 : 62 - 62
  • [28] Rapid CYP2C19 Genotype Testing: Comparison between Spartan RX CYP2C19 and Verigene CYP2C19
    Zhou, Y.
    Armstead, A. R.
    Coshatt, G. M.
    Brott, B. C.
    Sankaranarayanan, A.
    Limdi, N. A.
    Harada, S.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 845 - 845
  • [29] Influence of CYP2C19*2/*17 genotype on adverse drug reactions of voriconazole in patients after allo-HSCT: a four-case report
    Sienkiewicz Beata
    Urbaniak-Kujda Donata
    Dybko Jarosław
    Wróbel Tomasz
    Wiela-Hojeńska Anna
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 1103 - 1106
  • [30] Assessment of CYP2C19 genetic polymorphisms in a korean population using a simultaneous multiplex pyrosequencing method to simultaneously detect the CYP2C19*2, CYP2C19*3, and CYP2C19*17 alleles
    Kim, K. -A.
    Song, W. -K.
    Kim, K. -R.
    Park, J. -Y.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2010, 35 (06) : 697 - 703
12345